Cytogen demonstrates benefits of ProstaScint:
This article was originally published in Clinica
Executive Summary
Clinical trials of Cytogen's prostate cancer imaging agent, ProstaScint, demonstrate its possible use in selecting patients for salvage pelvic radiotherapy following radical prostatectomies. The indium-111 capromab pendetide compound is scheduled for review by the FDA's Medical Imaging Drug Advisory Committee in July. The New Jersey-based company presented the results of the trials at the AUA meeting.